Neglect Treatment by Prism Adaptation in the Acute Phase
Launched by UNIVERSITY OF GENEVA, SWITZERLAND · Oct 5, 2023
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called prism adaptation to help people who have a condition called unilateral spatial neglect (USN) after a brain injury, such as a stroke or brain tumor surgery. USN makes it hard for patients to pay attention to one side of their surroundings, which can make daily activities very challenging. The study aims to find out if using special glasses with prisms can improve attention and overall functioning when applied early in the recovery process. Participants will receive five treatment sessions, and their progress will be monitored for three months to see how well the treatment works.
To be eligible for this trial, participants should have experienced their first neurological event affecting either the right or left side of the brain and have clear brain scans showing the injury. They should also have good vision and be diagnosed with USN. However, individuals with previous neurological or psychiatric disorders, significant cognitive impairments, or difficulties understanding tasks may not qualify. Participants can expect a supportive environment and to contribute to research that could greatly improve recovery options for others facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • First neurological event, affecting the right hemisphere or the left hemisphere (stroke, brain tumour post-surgery);
- • Structural images of the brain lesion available (magnetic resonance or tomographic scans);
- • Good Normal (or corrected) visual acuity;
- • Presence of USN, as assessed by a standard neuropsychological evaluation.
- Exclusion Criteria:
- • Previous neurological disorder and/or current or previous psychiatric disease.
- • Presence or suspicion of previous general cognitive deficits documented from the clinical dossier and/or suspicious of possible cognitive deficits ;
- • Presence of difficulty in task's comprehension preventing its completion;
- • Impossibility to sustain a research session of at least 30 minutes (e.g., attentional lability).
About University Of Geneva, Switzerland
The University of Geneva, located in Switzerland, is a prestigious research institution renowned for its commitment to advancing scientific knowledge and improving public health. With a strong emphasis on interdisciplinary collaboration, the university conducts cutting-edge clinical trials aimed at exploring innovative therapies and enhancing patient care. Its dedicated research teams, equipped with state-of-the-art facilities and a robust ethical framework, strive to translate scientific discoveries into practical applications, ultimately contributing to the global advancement of medical science and the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, Genf, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported